Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Biography

Meet the Editorial Board Member

Author(s): S.K. Balani

Volume 23, Issue 13, 2022

Published on: 23 January, 2023

Page: [1011 - 1011] Pages: 1

DOI: 10.2174/138920022313230123103843

Next »
[1]
Nishihara M, Ramsden D, Balani SK. Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters. Xenobiotica 2021; 51(6): 668-79.
[2]
Pusalkar S, Zhou X, Li Y, et al. Biotransformation pathways and metabolite profiles of oral [14C]Alisertib (MLN8237), an investigational Aurora A Kinase inhibitor, in patients with advanced solid tumors. Drug Metab Dispos 2020; 48: 217-29.
[3]
Wolenski FS, Xia CQ, Ma B, Han TH, Shyu WC, Balani SK. CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption. Eur J Drug Metab Pharmacokinet 2018; 43(3): 347-54.
[4]
Hariparsad N, Ramsden D, Palamanda J, DeKeyser JG, Fahmi OA, Kenny JR, et al. Considerations from the IQ induction working group in response to drug-drug interaction guidance from regulatory agencies: Focus on downregulation, CYP2C induction, and CYP2B6 positive control. Drug Metab Dispos 2017; 45(10): 1049-59.
[5]
Pusalkar S, Plesescu M, Milton M, Balani SK, Chowdhury S, Prakash S. Metabolism, excretion and pharmacokinetics of MLN3897, a CCR1 antagonist, in humans. Drug Metab Lett 2016; 10(1): 22-37.
[6]
Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J, et al. MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors. ACS Med Chem Lett 2015; 6(6): 630-4.
[7]
Yu H, Balani SK, Chen W, Cui D, He L, Humphreys WG, et al. Contribution of metabolites to P450 inhibition-Based Drug-Drug interactions: Scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group. Drug Metab Dispos 2015; 43(4): 620-30.
[8]
Balani SK. ‘Role of metabolism in drug development’ in The Handbook of Metabolic Pathways of Xenobiotics. John Wiley & Sons, Ltd: Chichester, UK 2014; pp. 215-31.
[9]
Palani S, Patel M, Huck J, Zhang M, Balani SK, Yang J, et al. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemother Pharmacol 2013; 72(6): 1255-64.
[10]
Yang JJ, Li Y, Chakravarty A, Lu C, Xia CQ, Chen S, et al. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237). Drug Metab Lett 2013; 7(2): 96-104.
[11]
Balani SK, Christopher LJ, Donglu Zhang, D. “Bile Collection for Human ADME Studies” in ADME-Enabling Technologies in Drug Design and Development Donglu Zhang and Sekhar Surapaneni (eds), John Wiley & Sons 2012.
[12]
Balani SK. Grapefruit Juice and Its Constituents as New Esterase Inhibitors. Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad. 2010; pp. 443-66.
[13]
Balani SK, Lu C, Cardoza K, Berg C, Zhang J, Lee FW. Proposed new addition to 3Rs for ethical and humane use of rats in pharmacokinetic studies – ‘Recycle’. Drug Metab Lett 2008; 2: 193-7.
[14]
Lu C, Berg C, Prakash SR, Lee FW, Balani SK. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma-Part III. In vitro-in vivo correlation with fluconazole. Drug Metab Dispos 2008; 36: 1261-6.

Rights & Permissions Print Cite
Article Metrics
11
2
© 2024 Bentham Science Publishers | Privacy Policy